Results 101 to 110 of about 6,563 (147)

Successful Treatment of MEK Inhibitor-Induced Paronychia in Neurofibromatosis with Photodynamic Therapy: A Case Report and Review of the Therapeutic Options. [PDF]

J Clin Med
Ambrogio F, Perillo T, Bonamonte D, De Marco A, Tirone B, Laface C, Cazzato G, Foti C, Mortato E.   +8 more
europepmc   +1 more source

Mitigation and management of adverse events associated with amivantamab therapy. [PDF]

Oncologist
Florez N, LeBoeuf NR, Rotow J, Marks JA, Sabari JK, Arrieta O, Baldotto C, Gosain R, Zawisza D, McDonald S, Dylgjeri E, Cifuentes P, McLellan B, Leighl NB.   +13 more
europepmc   +1 more source

Anifrolumab for refractory chilblain lupus erythematosus. [PDF]

Int J Womens Dermatol
Bulosan H, Kalus A, Thomason J, Cogen AL.   +3 more
europepmc   +1 more source

Paronychia an Epidemic [PDF]

The American Journal of the Medical Sciences
openaire   +2 more sources

Amivantamab, a bispecific epidermal growth factor receptor and mesenchymal-epithelial transition factor inhibitor, associated with ulcerative intertrigo. [PDF]

JAAD Case Rep
Concannon HR, Ku RG, Brazel M, Selim MA, Fresco A.   +4 more
europepmc   +1 more source

Deceptive digits: squamous cell carcinoma of the nail bed masquerading as glomus tumor. [PDF]

J Surg Case Rep
Maheshwari N, Vardey M, Moon P, Jorwekar G.   +3 more
europepmc   +1 more source

Skin and Bone: Chronic Paronychia Leading to Osteomyelitis. [PDF]

Skin Appendage Disord
de Vries J, Chung M, Elewski BE.
europepmc   +1 more source

Evolving treatment strategies for EGFRex20ins-mutated NSCLC: a comprehensive review of Amivantamab's role and future directions. [PDF]

Ecancermedicalscience
Pereira RA, Tumelero M, Schwengber WK, Lenz G.   +3 more
europepmc   +1 more source

Chronic occupational paronychia secondary to digital pilonidal sinus from dog grooming. [PDF]

J Occup Health
Räisänen MP, Furu H, Reito A, Bindra RR.   +3 more
europepmc   +1 more source